跳至主要内容
临床试验/NCT00238498
NCT00238498已完成2 期

A Clinical Study to Assess the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes

Novartis0 个研究点目标入组 291 人开始时间: 2004年7月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
Novartis
入组人数
291
主要终点
Change from baseline in HbA1c at 12 weeks

研究概览

简要总结

This study was not conducted in the United States. The purpose of this study was to assess the safety and effectiveness of a number of doses of vildagliptin, an unapproved drug, in the treatment of people with type 2 diabetes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
20 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of type 2 diabetes
  • Patients who have been placed on diet and exercise therapy without achievement of glycemic control
  • Outpatients

排除标准

  • Type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes
  • Significant cardiovascular diseases
  • Significant diabetic complications
  • Other protocol-defined exclusion criteria may apply

结局指标

主要结局

Change from baseline in HbA1c at 12 weeks

次要结局

  • Change from baseline in HOMA B at 12 weeks
  • Change from baseline in HOMA IR at 12 weeks
  • Change from baseline for postprandial glucose at 12 weeks
  • Change from baseline on fasting plasma glucose at 12 weeks
  • Change from baseline on postprandial glucose AUC at 12 weeks

研究者

发起方
Novartis
申办方类型
Industry

相似试验